Acromegaly

Lore & Background

Acromegaly results from excess growth hormone (GH) after the growth plates have closed, typically beginning with enlargement of the hands and feet. Other features include enlargement of the forehead, jaw, and nose, as well as joint pain, thickened skin, deepening of the voice, headaches, and vision problems. Complications may include type 2 diabetes, sleep apnea, and high blood pressure. About 98% of cases are caused by a benign pituitary adenoma that overproduces GH and may compress surrounding brain tissues, including the optic nerves. Some adenomas grow slowly, with symptoms unnoticed for years, while others grow rapidly and invade nearby areas. Most pituitary tumors arise from a genetic mutation acquired during life, not inherited. In rare cases, tumors of the pancreas, lungs, or adrenal glands produce GH or GHRH, leading to acromegaly.

Reader's Guide

Acromegaly is significant as a chronic endocrine disorder that, if untreated, reduces life expectancy by about 10 years. Its diagnosis relies on measuring GH after glucose consumption or insulin-like growth factor I levels, followed by pituitary imaging. Treatment options include surgical removal of the tumor (preferred for smaller tumors), somatostatin analogues (e.g., octreotide, lanreotide), dopamine agonists (e.g., cabergoline), growth hormone receptor antagonists (e.g., pegvisomant), and radiation therapy. With treatment, life expectancy is not reduced. The condition also has a differential diagnosis called pseudoacromegaly, which presents similar features but without elevated GH or IGF-1. The legacy of acromegaly lies in its illustration of how a single hormonal imbalance can produce widespread physical and metabolic effects, and in the development of targeted therapies that improve outcomes.

Did You Know?

• About 98% of acromegaly cases are due to a benign pituitary adenoma.
• The initial symptom is typically enlargement of the hands and feet.
• Without treatment, life expectancy is reduced by 10 years; with treatment, it may still be somewhat reduced compared to the general population.
• Pegvisomant, a growth hormone receptor antagonist, controls disease activity in many patients, though some have an incomplete response or require combination therapy.

The Body's Slow Reshaping

Acromegaly is a condition in which the body continues to grow in specific regions long after the skeletal growth plates have sealed shut. The driving force behind this unwanted expansion is an overabundance of growth hormone circulating in the bloodstream. The earliest and most recognizable signs typically appear in the hands and feet, which gradually enlarge. Over time, the forehead, jaw, and nose also become more prominent, while the skin thickens across the body. The voice deepens noticeably as the vocal cords thicken, and speech may slow. The skull itself can expand, producing a pronounced brow ridge and a forward-projecting lower jaw accompanied by an oversized tongue and gaps between the teeth. Soft tissues swell throughout, affecting the heart's muscular wall, the kidneys, and the vocal apparatus. Patients frequently report joint pain, headaches, and visual disturbances. Additional features include excessive hair growth, darkened skin patches, heavy sweating, and the appearance of small skin tags. Nerve compression, particularly in the wrist, can produce the familiar tingling and numbness of carpal tunnel syndrome.

A Single Cell's Rebellion

In roughly ninety-eight percent of cases, acromegaly traces back to a benign pituitary tumor called an adenoma. This tumor does not stem from inherited genetics; it typically begins when a single pituitary cell acquires a mutation later in life. That mutation disrupts a gene responsible for relaying chemical signals within the cell, effectively locking the division-and-secrete pathway in a permanently active state. The rogue cell then multiplies and floods the body with growth hormone unchecked. As the adenoma enlarges, it presses against neighboring brain structures and, in some instances, the optic nerves, producing headaches and visual disturbances. It can also squeeze the healthy pituitary tissue around it, disrupting other hormone balances and causing menstrual irregularities or breast discharge in women and impotence in men due to reduced testosterone. The pace of growth varies enormously: some adenomas creep forward so slowly that symptoms go unnoticed for years, while others, more common in younger patients, expand rapidly and invade adjacent sinuses or brain regions. In rare cases, tumors of the pancreas, lungs, or adrenal glands can trigger the same hormonal excess by producing growth hormone directly or by secreting the releasing hormone that prompts the pituitary to overproduce it.

Unmasking the Condition

Confirming a diagnosis of acromegaly begins with blood work. A clinician will measure the patient's growth hormone level after they have consumed a glucose solution, or alternatively check the concentration of insulin-like growth factor I circulating in the blood. Once elevated levels are confirmed, the next step is imaging the pituitary region of the brain. An MRI focused on the sella turcica, performed after administering a gadolinium contrast agent, provides a clear picture of the pituitary gland, the hypothalamus, and the precise location of any tumor. It is important to distinguish acromegaly from a look-alike condition called pseudoacromegaly, in which the characteristic physical features are present but growth hormone and IGF-1 levels remain normal. Pseudoacromegaly is frequently linked to insulin resistance and has been reported in cases involving unusually high doses of the medication minoxidil, as well as in instances of a selective post-receptor defect in insulin signaling that impairs metabolic pathways while preserving cell-growth signaling. Additionally, if the same excess of growth hormone occurs during childhood before the growth plates close, the resulting condition is called gigantism rather than acromegaly, and it is marked by excessive height rather than the localized overgrowth seen in adults.

Restoring Balance: Treatment and Outlook

The cornerstone of acromegaly treatment is surgical removal of the pituitary adenoma, and the smaller the tumor, the greater the chance that surgery alone will be curative. When surgery is not feasible or does not fully resolve the hormonal excess, doctors turn to medications. Somatostatin analogues such as octreotide and lanreotide are the primary pharmacological tools; they can also be used to shrink a large tumor before an operation. However, long-term use carries side effects: roughly one-third of patients experience digestive issues like loose stools, nausea, and gas, while about twenty-five percent develop gallstones, usually without symptoms. In some cases, the medication can even provoke diabetes by suppressing insulin release. For aggressive adenomas that resist standard treatment, a second-generation analogue called pasireotide may be employed, though insulin and glucose levels must be monitored closely. Radiation therapy remains a fallback when neither surgery nor drugs achieve full control. The prognosis difference is stark: left untreated, acromegaly shortens life expectancy by approximately ten years, but with appropriate treatment, life expectancy is not reduced.